Editorial: Advances in the treatment of chronic myeloid leukemia

Frontiers in Oncology

Oncology

Mario Tiribelli¹  Jignesh Dalal²  Ahmet Emre Eşkazan³  Chung H. Kok⁴  David Yeung⁵ 

[1]Division of Hematology and Bone Marrow Transplant, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) – Udine Hospital, Udine, Italy

[2]Department of Medicine, University of Udine, Udine, Italy

[3]Division of Hematology and Bone Marrow Transplant, Rainbow Babies and Children’s Hospital, OH, United States

[4]Case Western Reserve University, Cleveland, OH, United States

[5]Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye

[6]Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia

[7]Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia

[8]Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia

[9]Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia

[10]Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia

[11]Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia

[12]Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia

关键词: adverse event;    arterial occlusive event;    BCR::ABL1 transcript;    COVID-19;    quality of life;    stem cell transplantation;    treatment-free remission;    tyrosine kinase inhibitor;   

DOI  :  10.3389/fonc.2023.1166588

 received in 2023-02-15, accepted in 2023-02-22,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Eşkazan, Kok, Yeung, Dalal and Tiribelli